Cocrystal Pharma
COCP
21 hedge funds and large institutions have $8.39M invested in Cocrystal Pharma in 2020 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 9 closing their positions.
162% more capital invested
Capital invested by funds: $3.2M → $8.39M (+$5.19M)
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0.16% more ownership
Funds ownership: 0.72% → 0.88% (+0.16%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less funds holding
Funds holding: 24 → 21 (-3)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.58M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$227K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$41.4K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$40K |
| 5 |
BJL
Brighton Jones LLC
Seattle,
Washington
|
+$18.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$278K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$181K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$133K |
| 4 |
BlackRock
New York
|
-$26K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$21.4K |
COCP Hedge Fund Activity: Q2 2020 in Review
21 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q2 2020, worth a combined $8.39M — up 162% from $3.2M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of COCP and 6 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.58M. The largest seller was Sabby Management, exiting entirely with an estimated $278K sold.
- 21 institutional investors held Cocrystal Pharma (COCP) as of Q2 2020, down from 24 in Q1 2020.
- Funds reported $8.39M of Cocrystal Pharma stock for Q2 2020, up 162% quarter-over-quarter.
- 6 funds opened new Cocrystal Pharma positions in Q2 2020 and 9 closed out, a net change of -3 holders.
- The largest Cocrystal Pharma buyer in Q2 2020 was Renaissance Technologies, an estimated $1.58M added.
- The largest Cocrystal Pharma seller in Q2 2020 was Sabby Management, an estimated $278K sold.
Based on aggregated 13F filings for Q2 2020.